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Abstract
Background: Congenital adrenal hyperplasia (CAH) cause life-threatening adrenal crisis. It also affects fetal sex
development and can result in incorrect sex assignment at birth. In 1989, a newborn screening program for
congenital adrenal hyperplasia (CAH) was introduced in Tokyo. Here we present the results of this screening
program in order to clarify the efficiency of CAH screening and the incidence of CAH in Japan.
Method: From 1989 to 2013, a total of 2,105,108 infants were screened for CAH. The cutoff level for diagnosis of
CAH was adjusted for gestational age and birth weight.
Results: A total of 410 infants were judged positive, and of these, 106 patients were diagnosed with CAH, indicating a
positive predictive value (PPV) of 25.8 %. Of the 106 patients, 94 (88.7 %) were diagnosed with 21-OHD. Of these 94
patients, 73 were diagnosed with the salt wasting form, 14 with the simple virilising form and 7 with the nonclassical
form (NC21OHD). The mean birth weight and gestational age were 3192 ± 385 g and 38.9 ± 1.38 weeks. 11 out of 44
female patients were assigned as female according to their screening result.
Conclusions: These data suggest that the newborn screening in Tokyo was effective, especially for sex assignment and
preventing fatal adrenal crisis. The incidence of CAH was similar to that measured in previous Japanese screening
studies, and it was also similar to that of western countries. The incidence of NC21OHD in Japan in the present study
was lower than that in western countries as previous studies reported. The screening program achieved higher PPV
than previous CAH screening studies, which might be due to the use of variable cutoffs according to gestational age
and birth weight. However, most of the neonates born at 37 weeks or less that were referred to hospital were false-
positives. Further changes are needed to reduce the number of false positive preterm neonates.
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Background
Congenital adrenal hyperplasia (CAH) is an inherited dis-
order caused by the loss or severely impaired activity of
steroidogenic enzymes involved in cortisol biosynthesis.
More than 90 % of cases result from 21-hydroxylase defi-
ciency (21-OHD) caused by mutations in CYP21A2 [1, 2].
The prevalence of 21-OHD has been estimated at 1 in
18,000. According to the clinical phenotypes, the disease
is classified into three forms, the salt wasting (SW) form
and the simple virilising (SV) form, which are also called
the classical form, and the nonclassical (NC) form. The
SW form is the severest. Virilisation of external genitalia
in newborn females and precocious puberty due to over-
production of androgens from the adrenal cortex are
major clinical problems of both the SW and SV forms. In
the SW form, in addition to overproduction of androgens,
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aldosterone is deficient and it causes life-threatening ad-
renal crisis.
In order to prevent life-threatening adrenal crisis and
to help make the appropriate sex assignments in affected
female patients, newborn mass screening programs for
CAH have been introduced in many countries including
Japan [3–5]. The aim of our study was to summarize the
results of the past 23 years of newborn mass screening
for CAH in Tokyo. Specifically, we wished to determine
the efficiency of CAH screening and the incidence of
CAH in Tokyo.
This study is the largest retrospective analysis of CAH
newborn screening by using a single screening program
in East Asia [6–10]. Tokyo is the largest city accounting
for more than 10 % of the population in Japan [11], and
to date, more than two million neonates have been
screened. False positives for CAH in preterm infants is
one of the major concerns of newborn screening pro-
grams [2]. In a pilot study from 1984 to 1987, we found
that we could reduce the number of false positives by
using higher cut-offs for preterm or low birth weight in-
fants from that for term infants, and used these different
criteria throughout the screening program.
The positive predictive value of our study was




From 1 January, 1989 to 31 March, 2013, neonates
born in Tokyo were screened. Basically we recom-
mended collecting the blood sample from the age of
4 to 7 days, and clinical data was obtained by follow-
up survey from each hospital where neonates judged
as positive at screening were referred.
Measurement of 17-OHP and criteria
Blood samples were collected by a heel prick blotted
on a filter paper after written informed consent
was obtained from parents. The level of 17-
hydroxyprogesterone (17-OHP) was initially deter-
mined by enzyme linked immunosorbent assay (ELISA)
(Siemens Medical Solutions Diagnostics, CA, U.S.)
without steroid extraction. Blood samples in the 97th
percentile or higher of 17-OHP values were subjected
to the second ELISA (Eiken Chemical CO., LTD, Tokyo,
Japan) after steroid extraction (Fig. 1). The measured
values on the second assay were doubled to be equiva-
lent to the serum levels. Sex, birth weight, and gesta-
tional age were recorded in the application form for the
screening test, so we obtained these data from all neo-
nates who underwent the screening. The cutoff level of
17-OHP was adjusted according to 1) gestational age
(GA) at birth, 2) corrected gestational age at the time
of the test and 3) body weight at the time of the test
(Table 1). The cutoffs were determined according to
our pilot study of serum 17-OHP levels in term and
preterm infants. The criteria for preterm and low birth
weight infants were used from the start of the screening
in Tokyo. The algorithm and criteria of the screening
are shown in Table 1 and Fig. 1. Briefly, the patients
whose results were “re-tests” were recalled to repeat a
test of 17-OHP measurement, and the test was per-
formed at the hospital where the patients were born. If
the level of 17-OHP was higher than 60 nmol/L or still
higher than normal range on the third test, the patient
was considered to be positive. The patients with “posi-
tive” results were referred to pediatric endocrinologists
for further endocrinological evaluation.
Follow-up survey
We performed follow-up survey of the patients who
were referred to hospitals. We collected clinical infor-
mation of the patients from the physicians of the hos-
pitals. The collected information included the
diagnosis of the patients including the type of CAH,
laboratory data before the start of the treatment (17-
OHP, Na, K), and the brief clinical course during the
early infantile period. We gathered the surveys of all
patients who were referred to the hospitals. The
present retrospective analysis was approved by the
ethics committee of Tokyo Health Service Association
(No. 2014–2–1).
Results
Firstly, we comprehensively analysed our data, includ-
ing the incidence and the positive predictive value
(PPV) of the screening. Subsequently, we examined
the clinical details of the CAH patients who were
identified by our screening, and finally, one of the
purposes of the screening, sex assignment issue, was
analysed.
Incidence and positive predictive value of the screening
A total of 2,105,108 neonates were screened. Cover-
age of the screening was 93 % of newborn babies in
Tokyo registered in Vital Statics of Japan [12]. Of
these, 410 neonates had positive results and were re-
ferred to hospitals. The median age at first screening
was 5 days (range 0–62 days), consistent with our
recommendation. Of the 410 neonates, 106 were diag-
nosed with CAH, resulting in an incidence of
1:19,859 (Table 2). Diagnosis of CAH was based on
the endocrinological data and physical findings [13].
Genetic tests were not carried out in all cases.
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Of 300 infants born at term, 100 were diagnosed as
having CAH, resulting in a positive predictive value
(PPV) of full-term neonates of 33.3 %. Even though
the criteria were applied according to gestational age,
99 (24.1 %) were preterm infants with a positive re-
sult. Thus, the PPV of preterm neonates who were
born before 37 weeks gestation was only 2 % (2/99),
resulting in 25.8 % (106/410) of the total PPV of the
screening (Table 3).
The gestational age of the 21-OHD patients was
distributed in a bell-shape curve with a single peak
(Fig. 2), however, the gestational age distribution in
the referred neonates showed two peaks at 39 and
37 weeks, resulting in lower predictive value of the
screening for infants born at 37 weeks gestation or
before. These data suggest that neonates, even at
37 weeks of gestational age, tend to show unspecific
elevation of serum levels of 17-OHP by cross-
Table 1 Criteria of CAH mass screening in Tokyo
<Criteria according to the gestational age >
Gestational age at birth (weeks)a ≤29 30–34 35–36 37–
Corrected gestational age (weeks)b ≤31 32–35 36–37 38–
<Criteria according to weight >c,d
Body weight (g) ≤999 1,000–1,999 2,000–2,499 2,500–
Cutoff level of 17-OHP [nmol/L] Reteste 60 45 24 15
Positivef 60 60 60
aSamples collected before the age of 7 days
bSamples collected at the age of 7 days or after
c1st test: Body weight = Birth weight. 2nd test and after: Body weight = Corrected body weight calculated by the formula as below. Corrected body weight at test
(g) = birth weight (g) + (age at test – 7) × 20 (g)
dFor infants born small or large for gestational age, either the criteria of gestational age (corrected gestational age) or body weight was applied, whichever was
lower value
erecall for the second (or the third) test of the screening
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Eluted assay of 17-OHP
Fig. 1 Algorithm of CAH screening in Tokyo. Abbreviation: 17-OHP: 17-hydroxyprogesterone
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reaction for adrenal steroids from fetal adrenal cortex
(Fig. 2).
Clinical details of CAH patients identified by the
screening
The gestational ages and the birth weights were 38.9 ±
1.38 weeks and 3192 ± 385 g (Table 4). In 2009, the aver-
age birth weight of single births in Japan was 3020 g,
and the incidence of preterm births was 4.7 % [14],
which are not significantly different from those of the
21-OHD patients in Tokyo.
Two preterm neonates were diagnosed with 21-OHD.
Both were born at 36 weeks and their birth weights were
2570 g and 2770 g, respectively. None of the 21-OHD
patients were born before 36 weeks. Only one patient
was born as low birth weight infant with 2380 g at
40 weeks.
Information on the type of CAH was available for 96
patients in the survey. All but two of these patients had
21-OHD. In addition, two of these patients had 3β-
hydroxysteroid dehydrogenase deficiency. The most fre-
quent type of 21-OHD was the salt wasting form, ac-
counting for 73 of the 94 patients. Fourteen of the 21-
OHD patients had the simple virilising form and seven
had the nonclassical forms. The incidence of nonclassi-
cal forms was low, approximately 1:300,729 as reported
previously in Japan [15–17].
The mean values of the levels of 17-OHP on the first
test in SW, SV and NC were 676.5, 146.3, and 29.2 nmol/
L, respectively (Fig. 3). Although these values were
Table 3 Positive predictive value of the screening and
incidence of CAH in Tokyo. Positive predictive value on term
and preterm infants
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Fig. 2 Birth weights (a) and gestational ages (b) of patients and
newborns judged as positive in CAH screening. Abbreviation: CAH:
congenital adrenal hyperplasia; N.A.: data not available
Table 4 Clinical characteristics and the details of the screening





Changed from male to female 2
Assigned to female by screening 9
Data not available 6
Gestational Age
Preterm (<37 weeks) 2 (1.90)
Term 100 (94.3)
Data not available 4
Form of CAH
21-OHD 94 (88.7)
Salt Wasting (SW) 73
Simple Virilising (SV) 14
Nonclassical (NC) 7
3β-HSDD 2 (1.89)
Data not available 10
Gestational Age [weeks] (Mean ± SD) 38.9 ± 1.38
Birth weight [g] (Mean ± SD) 3192 ± 385
Table 2 Positive predictive value of the screening and
incidence of CAH in Tokyo. Overview of the screening results
Category Number (Percent)
Total infants tested 2,105,108 (100)
Retested 7,940 (0.38)
Positive 410 (0.02)
CAH patients 106 (0.005)
Positive predictive value 25.8 %
Incidence of CAH by screening 1:19,859
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significantly different, they substantially overlapped, sug-
gesting that it is inappropriate to predict the form of CAH
according to the value of 17-OHP.
On the first test, most SW patients (94.5 %) showed
remarkably elevated levels of 17-OHP, and were re-
ferred to hospitals (Table 5). While, four SW patients
(Nos. 53, 84, 99, 101) showed mildly elevated levels of
17-OHP on the first test (Table 6) and required re-
peated tests. These results suggest that mildly elevated
17-OHP does not exclude the possibility of classical 21-
OHD. On the other hand, none of the NC patients
were discovered on the first test, suggesting that it is
not likely to be the NC form of 21-OHD (NC21OHD)
whose 17-OHP was remarkably elevated on the first
test (Table 5). No fatal cases were reported by follow-
up survey.
Screening-assisted sex assignments
Of the 106 CAH patients, 56 were males, 44 were fe-
males and the information of the sex in 6 cases was not
available on the survey (Table 4). Two of the patients
originally thought to be males were reassigned as fe-
males according to the screening results. Nine patients
were assigned as females according to the screening re-
sults (Table 4).
If the patients without information of assigned sex
were female with ambiguous genitalia, the total number
of female patients might be 50, and the sex assignment
of 17 female patients would have been assisted by the
screening results.
Discussion
Our study revealed the incidence of CAH in Tokyo was
1/19,859. In Japan, newborn screening has been carried
out in each prefecture independently with different cri-
teria and different follow-up survey systems. Thus, it has
been difficult to have a large-scale study of the screen-
ing. Suwa’s meta-analysis in Japan and Morikawa’s ana-
lysis in Sapporo reported the incidence of CAH was 1/
18,827 and 1/20,756 [10, 18]. The incidences in these
studies were very similar to our data. We assume that
the incidence of CAH in Japan is approximately 1/
20,000.
Our data suggests that the screening was performed
properly. One of the aims of the screening is to assist
proper sex assignment in 46, XX patients. It was re-
ported that, before the neonatal screening program
started, 12 % of 46,XX patients were incorrectly assigned
to male [19]. Therefore, our data strongly suggest that
the screening assisted in the sex assignment of CAH
patients.
The another objective of the screening is to prevent
fatal adrenal crisis during the neonatal period. The
screening program might contribute to decreasing the
mortality by preventing neonatal fatal adrenal crisis with
few false negative cases. Despite our screening program
lacked the system to detect false negative patients, none
of the cases who were missed by the screening program
were reported to be fatal by pediatric endocrinologists in



















Fig. 3 Serum levels of 17-OHP in CAH patients at the first tests.
Abbreviation: 17-OHP: 17-hydroxyprogesterone; 21-OHD: 21-
hydroxylase deficiency; SW: salt wasting; SV: simple virilising; NC:
nonclassical. **, p < 0.01(ANOVA)
Table 5 Clinical characteristics and the details of the screening
of 106 CAH patients. The number of tests to be assessed
positive in each form of 21-OHD
Number
of test
SW SV NC Total
(n = 73) (n = 14) (n = 7) (n = 94)
Number of patients (%)
1 69 (94.5) 8 (57.1) 0 (0) 77 (81.9)
2 3 (4.11) 3 (21.4) 2 (28.5) 8 (8.51)
≥3 1 (1.37) 3 (21.4) 5 (71.4) 9 (9.57)
Upper: The number of the patients
Lower (%): The proportion to the total number of patients in each form
Table 6 Clinical characteristics and the details of the screening
of 106 CAH patients. 17-OHP values of SW patients tested
repeatedly
17-OHP result [nmol/L]
First test Second test Third test
Twice
Patient No.53 49.09 339.97
Patient No.99 16.97 90.90
Patient No.101 40.60 244.22
Three times
Patient No.84 47.57 27.27 23.94
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in Japan have been attributed to CAH [20]. Further, no
mortalities from CAH have been attributed to false neg-
atives after the start of newborn screening programs in
Japan [21]. The screening programs have decreased mor-
tality rate due to CAH from 6.8 % to 1.2–4.0 % [21].
Because CAH screening results in many false positives
in preterm infants [2], we used cut-off criteria for pre-
term infants and low birth weight infants that were
higher than those used for term infants. The recall ratio
(0.19 %) was lower and the PPV (25.8 %) was higher
than those of other reports (Table 7) [5, 9, 10, 22–25],
especially when compared to two other studies from
Japan that did not use different cut-off criteria for pre-
term infants. Indeed, the ratio of the number of referred
term infants to the number of preterm infants (3.03) was
much higher than the ratios in other reports (Table 7),
suggesting that our program eliminated false positive
cases of preterm or low birth weight infants. We con-
cluded that using cut-off criteria for preterm infants and
low birth weight infants was effective at reducing false
positive cases.
Even though our PPV was higher than the PPVs in
other screening systems, it was still only 25 %, indi-
cating that the efficiency of our screen program at
eliminating false positive cases is limited. Unspecific
cross-reactions for adrenal steroids from fetal adrenal
cortex have been reported to cause false positive re-
sults in preterm infants [26]. The high false-positive
rate is one of the major concerns of CAH newborn
screening, and introducing novel assay systems with
higher specificity for 17-OHP might achieve more effi-
cient screening [27–29]. A recently developed assay sys-
tem, that uses tandem mass spectrometry, has been
reported to have extremely high specificity for steroid as-
says and might be considered for a future assay system
[30, 31].
The incidence of NC21OHD patients identified by the
screening was lower than the incidence in European coun-
tries and the U.S. [4, 25], and is consistent with previous
reports from Japan [15–17]. It is difficult to predict the
incidence of NC21OHD according to the newborn screen-
ing results because patients with the NC form are usually
missed by newborn screening [32]. However, it has been
assumed that the incidence of NC21OHD in Japan would
be lower than that of western countries [16, 17]. In west-
ern countries, nonclassical cases are mainly caused by
V281L mutation in CYP21A2 that is rare in Japanese pa-
tients [1, 16, 33]. In Japan, a P30L mutation is the major
genetic cause for NC21OHD, although the frequency of
P30L in Japan is much lower than that of V281L in west-
ern countries, resulting in a lower incidence of NC21OHD
in Japan [16].
In our study, two patients were diagnosed with 3β-
HSDD, suggesting that a careful diagnostic approach is
essential to differentiate other types of CAH from 21-
OHD. The serum level of 17-OHP is known to be ele-
vated in other forms of CAH, such as 11β-hydroxylase
deficiency (11-OHD) and cytochrome P450 oxidoreduc-
tase deficiency (PORD). Even in 3β-HSDD, the 17-OHP
level is reported to be paradoxically elevated, and occa-
sionally similar to that of 21-OHD [34]. These diagnos-
tic problems are potential clinical pitfalls in diagnosing
the type of CAH. Including sex assignment, a different
clinical approach is required for each type of CAH. In
terms of the type of CAH, it should be noted that 11-
OHD patients were not reported in our screening sur-
vey. The incidence of 11-OHD has been reported to be
much higher than that of 3β-HSDD, and we cannot ex-
clude the possibility that some 11-OHD patients were
incorrectly diagnosed.
The limitation of this study is lack of the system to col-
lect the information on false negative cases and didn’t de-
tect precise number of false negatives.
Conclusion
Newborn screening in Tokyo was performed effectively
for sex assignment and preventing fatal adrenal crisis,
contributing to correct sex assignment and reduce mor-
tality. The incidence of classical 21-OHD was similar to
that of western countries, although the incidence of NC
Table 7 Proportion of preterm infants among published studies
Number of Patients Referred to Clinical Hospital PPV, % Variable 17-OHP cutoff criteria
Reference n Total (%) Term Preterm N.A. A/B GA Birth weight
(A) (B)
The Netherland, 2001 [24] 87,827 224 (0.255) 70 150 4 0.47 5.9 Yes Yes
France, 2012 [22] 6,012,798 15,407 (0.256) 1,058 10,562 3,787 0.10 2.3 No No
Sweden, 2014 [5] 2,737,932 1728 (0.063) 874 854 0 1.02 13.4 Yes Yes
Niigata, Japan, 2011 [9] 478,337 242 (0.050) 69 173 0 0.39 10.7 No No
Sapporo, Japan, 2014 [10] 251,922 880 (0.349) 170 708 2 0.24 N.A. No No
Tokyo, Japan, 2015 2,105,108 410 (0.019) 300 99 11 3.03 25.8 Yes Yes
Abbreviation: PPV: Positive Predictive Value; GA: Gestational Age; N.A.: data not available
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was much lower than reported previously in western
countries. The PPV appeared to be improved by adjust-
ing the cutoffs for gestational age and for body weight,
although the PPV for preterm infants was still low. To
reduce the number of false positive cases, assay systems
with higher specificity are needed.
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